Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CALI $2.50 only 3.7M O/S! Warming up!!!
The BHC is a very elite group! Don't be so hard on your self!!!
MSTX, a publicly traded biopharmaceutical company headquartered in San Diego, CA; with a twelve-month price target of $2.25. Ross Silver, Principal Analyst at Vista Partners, stated, "MSTX completed an underwritten public offering in June with institutional investors that include Franklin Resources (BEN), Deerfield Capital Management & others that collectively own approximately 50% of MSTX post the offering. Attracting these prestigious investors to fully fund their Phase 3 sickle cell trial is encouraging." Mr. Silver continued, "Per the first quarter earnings release on May 15, 2013; MSTX has opened more than a dozen clinical sites in EPIC and is on track to meet its goal of opening approximately 40 U.S. sites by year-end. MSTX plans to support U.S. enrollment by opening roughly 30 sites outside the U.S., beginning early next year. MSTX remains the only company with a new drug in phase 3 development in sickle cell disease and investigators have been enthusiastic about the potential for MST-188 to become the first agent approved to treat an on-going vaso-occlusive crisis of sickle cell disease.
MSTX .53 hod!!!
NEON Neonode Signs License Agreement With Lierda Science & Technology Group Co., Ltd for a New Multi-Purpose Outdoor and Industrial Touch Platform
MSTX! Mast Therapeutics (MSTX) focuses on developing therapies for serious or life-threatening diseases. Its lead product candidate includes MST-188, a product candidate that has hemorheologic, cytoprotective, and anti-inflammatory properties, which is in phase 3 study for the treatment of sickle cell disease in patients. I rarely cover stocks that sell for less than $1 a share, but I will make an exception for this speculative biotech play.
One very interesting thing about Mast is that its entire market capitalization is represented by the net cash on its balance sheet after a recent secondary offering. The other thing that caught my eye on this stock was a report from Canaccord Genuity this week on this fifty cent a share stock. The analyst firm initiated the shares with a whopping $3 a share price target. Its analyst noted "We think MST-188 could gain significant market share given the unmet need in SCD and potential combo-Tx. Our $3.00 target is based on NPV analysis."
This is a speculative play for patient long term investors. Even Canaccord's analyst does not see a launch of MST-188 until 2017, although he also puts eventual peak sales at $400mm annually. Only three analysts cover this ~$50mm market capitalization concern. Their price targets range from $1 to $3 a share.
Boing! Bids stacking!!!
TWTRQ trading at a penny and some thought it was Twitter! Their trading accounts should be closed immediately!!!
MSTX Mast Therapeutics Inc; A Potential Ten Bagger!
http://seekingalpha.com/instablog/6472041-thomas-almond/2144282-mast-therapeutics-inc-a-potential-ten-bagger?source=kizur
My thoughts as well! Check his/her brokerage account for TSLA puts bought in size!!!
Now that's an awesome fill you got!!!
That's one way to defund obamacare!!!
What notice on DCTH?
Looking forward to tomorrow!!!
Thx oh wise one!!!
Will this trade premarket at split adjusted price?
Yikes! Glad I'm already out!!!
Absolutely!!!
RNN over .47 dance card is filling up!!!
RNN .46 hod! The dance is starting!!!
ARO it may not be much of a premium, if any!!!
Asleep at the wheel! Only wish I had bought more!!!
DCTH could be a multi day runner ZLCS style!!!
DCTH .47 looking for .50 break!!!
NVGN 4.36 continues! Watch the volume, only 5M O/S!!!
DCTH starter @ .41! U.S. FDA GRANTS ORPHAN DRUG DESIGNATION TO DELCATH SYSTEMS FOR USE OF MELPHALAN HYDROCHLORIDE IN HCC
FATE Fate Therapeutics IPO Opens at $6.56 After Pricing at $6
Likely developments and expected results of operations
"The Company currently is engaged in discussions on two matters that, if successful, will have a significant impact on the Company’s structure and R&D activities.
The first matter concerns the acquisition of a novel drug technology that the Company believes complements the super-benzopyran drug technology and will assist the Company in its aim of delivering effective chemotherapy across a broad spectrum of both cancer phenotypes and genotypes.
The second matter concerns a collaborative structure that will allow the Company to work towards its goal of individualizing chemotherapy.
Both matters are expected to be concluded by the end of this year."
That would be great! I read the annual report from their website, lots going on behind the scenes!!!
NVGN 4.33! Over 4x avg volume on radar!!!
RNA 7.25 getting busy! Huge gap to fill!!!
Sold my last bit on Friday's little pop!!!
Feds even get a subsidy for their healthcare packages! I nver knew that!!!
RNN.45 Rexahn Pharmaceuticals Announces Publication of Preclinical Data for Novel Anti-Cancer Compound RX-3117
8:00a ET September 30, 2013 (Business Wire) Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing potential best-in-class oncology therapies, today announced the on-line publication of preclinical results for RX-3117 in a peer reviewed medical journal, Investigational New Drugs, in an article titled, "Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360)". Investigational New Drugs is an interdisciplinary journal presenting the latest investigations and discussions of critical questions appropriate to the entire field of new anticancer drug development.
New John Gilliam article out confirming CVSL buying shares!!!
BTH again!!!
RNA 6.40 hod! Huge gap to fill!!!
John Gilliam mentioning CVLS is building a position in Blyth
via FinancialJuice!!!
NEON $6.70 almost 30% short interest! On radar!!!
Ain't it the truth!!!